{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:57:03Z","timestamp":1794265023321,"version":"4.9.0"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS of the National Institute of Health","doi-asserted-by":"publisher","award":["SC3GM131986"],"award-info":[{"award-number":["SC3GM131986"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS of the National Institute of Health","doi-asserted-by":"publisher","award":["R16GM149412"],"award-info":[{"award-number":["R16GM149412"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Insights"],"abstract":"<jats:p>Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of hepatorenal syndrome. In cases where terlipressin therapy is accessible, the initial approach involves administering terlipressin alongside albumin. Terlipressin, a synthetic analog of vasopressin, boasts double the preference for vasopressin V1 receptors compared to V2 receptors. The FDA granted approval to terlipressin in September 2022, demonstrating its intrinsic activity, although a significant portion of its function arises from its transformation into lysine vasopressin. This article provides a comprehensive examination of terlipressin\u2019s various pharmacodynamic and pharmacokinetic facets, as well as its clinical utility, aiming to keep the scientific community well informed about its safe and efficient utilization.<\/jats:p>","DOI":"10.3390\/gastroent14040031","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:24:44Z","timestamp":1695889484000},"page":"420-430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile"],"prefix":"10.3390","volume":"14","author":[{"given":"Ahlam","family":"Ayyad","sequence":"first","affiliation":[{"name":"Division of Clinical and Administrative Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-2662","authenticated-orcid":false,"given":"Rami A.","family":"Al-Horani","sequence":"additional","affiliation":[{"name":"Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Schrier","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Guevara","year":"2003","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.01340406","article-title":"Hepatorenal syndrome: Pathophysiology and management","volume":"1","author":"Wadei","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cgh.2017.05.041","article-title":"New Developments in Hepatorenal Syndrome","volume":"16","author":"Mindikoglu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Escorsell","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-60-3-353","article-title":"The kidney in cirrhosis: I. Clinical and biochemical features of azotemia in hepatic failure","volume":"60","author":"Baldus","year":"1964","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"ref_12","first-page":"e16084","article-title":"A Review of Hepatorenal Syndrome","volume":"13","author":"Subedi","year":"2021","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/lt.24609","article-title":"Management of renal failure in end-stage liver disease: A critical appraisal","volume":"22","author":"Cheng","year":"2016","journal-title":"Liver Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.3748\/wjg.v16.i39.4905","article-title":"Alcoholic hepatitis 2010: A clinician\u2019s guide to diagnosis and therapy","volume":"16","author":"Amini","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.24109","article-title":"Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure","volume":"53","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3949\/ccjm.90a.22028","article-title":"Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome","volume":"90","author":"Khan","year":"2023","journal-title":"Cleve Clin J Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2044.2004.03877.x","article-title":"Vasopressin and terlipressin: Pharmacology and its clinical relevance","volume":"59","author":"Kam","year":"2004","journal-title":"Anaesthesia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/liv.14703","article-title":"Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives","volume":"40","author":"Kulkarni","year":"2020","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"(2023). Terlipressin Acetate. Am. J. Health Syst. Pharm., 80, e10\u2013e11.","DOI":"10.1093\/ajhp\/zxac291"},{"key":"ref_20","unstructured":"Attridge, R.L., Miller, M.L., Moote, R., and Ryan, L. (2013). Internal Medicine: A Guide to Clinical Therapeutics, McGraw Hill. Available online: https:\/\/accesspharmacy.mhmedical.com\/Content.aspx?bookid=565&sectionid=42003718."},{"key":"ref_21","unstructured":"Hammer, G.D., and McPhee, S.J. (2019). Pathophysiology of Disease: An Introduction to Clinical Medicine, McGraw Hill. [8th ed.]. Available online: https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=2468&sectionid=198222693."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00424-008-0498-1","article-title":"Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption","volume":"456","author":"Boone","year":"2008","journal-title":"Pflugers Arch."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.shk.0000158115.69704.11","article-title":"Terlipressin as rescue therapy for intractable hypotension due to septic shock in children","volume":"23","author":"Matok","year":"2005","journal-title":"Shock"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1345\/aph.1H373","article-title":"Terlipressin: Vasopressin analog and novel drug for septic shock","volume":"40","author":"Pesaturo","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_25","unstructured":"(2022, November 24). The U.S. Food and Drug Administration Label for TERLIVAZ (Terlipressin) for Injection, for Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022231s000lbl.pdf."},{"key":"ref_26","first-page":"691","article-title":"Terlipressin facilitates transport of septic patients treated with norepinephrine","volume":"8","author":"Klein","year":"2006","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00535-011-0485-8","article-title":"The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: A multicenter, open-label, explorative study","volume":"47","author":"Narahara","year":"2012","journal-title":"J. Gastroenterol."},{"key":"ref_30","unstructured":"(2023, August 04). Terlivaz\u00ae (Terlipressin) for Injection Prescribing Information. Available online: https:\/\/www.terlivaz.com\/assets\/pdf\/Terlivaz-USPI_04_2023.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/hep.31529","article-title":"Response to Terlipressin and Albumin Is Associated with Improved Liver Transplant Outcomes in Patients with Hepatorenal Syndrome","volume":"73","author":"Piano","year":"2021","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomised placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomised controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomised study","volume":"56","author":"Singh","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs. terlipressin in the treatment of type 2 hepatorenal syndrome: A randomised pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomised trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"ref_40","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: A prospective randomised trial","volume":"64","author":"Goyal","year":"2016","journal-title":"J. Assoc. Physicians India."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies","volume":"45","author":"Sanyal","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomised controlled study","volume":"37","author":"Saif","year":"2018","journal-title":"Indian. J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomised study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs. terlipressin in patients with hepatorenal syndrome: A prospective, randomised, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: A randomised study","volume":"134","author":"Guevara","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/2050640619825719","article-title":"Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2","volume":"7","author":"Rey","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_48","first-page":"1480A","article-title":"The CONFIRM study: A North American randomised controlled trial (RCT) of terlipressin plus albumin for the treatment of hepatorenal syndrome type 1 (HRS-1)","volume":"70","author":"Wong","year":"2019","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/apt.15836","article-title":"Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome","volume":"52","author":"Moore","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11606-017-4178-8","article-title":"Vasoactive agents for hepatorenal syndrome: A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"33","author":"Sridharan","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"ref_51","first-page":"CD013103","article-title":"Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: A network meta-analysis","volume":"9","author":"Best","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/CCM.0000000000005635","article-title":"Terlipressin: Leading the Water to the Thirsty","volume":"50","author":"Nanchal","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0168-8278(14)61096-5","article-title":"Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis","volume":"60","author":"Elia","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.34067\/KID.0000000000000217","article-title":"Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT","volume":"4","author":"Belcher","year":"2023","journal-title":"Kidney360"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Carter, J.A., Huang, X., Jamil, K., Corman, S., Ektare, V., and Niewoehner, J. (2023). Cost-effectiveness of terlipressin for hepatorenal syndrome: The United States hospital perspective. J. Med. Econ., 1\u201319.","DOI":"10.1080\/13696998.2023.2260693"}],"container-title":["Gastroenterology Insights"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7422\/14\/4\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:17Z","timestamp":1760130017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7422\/14\/4\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["gastroent14040031"],"URL":"https:\/\/doi.org\/10.3390\/gastroent14040031","relation":{},"ISSN":["2036-7422"],"issn-type":[{"value":"2036-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}